论文部分内容阅读
To investigate the changes of plasma brain natriuretic peptide (BNP) concentrations in patients with chronic heart failure (CHF) before and after carvedilol treatment. Methods Plasma BNP concentrations of patients with CHF (n=56) before and after carvedilol treatment and of normal controls (n=60) were measured with specific radioimmunoassay. Left ventricular ejection fraction of patients with CHF before and after carvedilol was measured with 99mTc gated cardiac blood pool scintigraphy. Results The results showed that plasma BNP concentrations of patients with CHF were significantly higher than that of normal controls [(222.65±78.52) ng·L-1 vs. (38.82±15.31) ng·L-1, P<0.01]. Plasma BNP concentrations had a significant negative correlation with left ventricular ejection fractions (r=-0.68,P<0.01). After three months treatment of carvedilol, plasma BNP concentrations fell to (79.65±69.52) ng·L-1(P<0.01), left ventricular ejection fractions increase from 34.41%±4.54% to 46.51%±5.38%(P<0.01). Conclusions These results indicate that plasma BNP concentrations are increased in patients with CHF, and markedly increased according to the severity of heart failure classified by NYHA classification. Carvedilol can markedly decrease plasma BNP concentrations and improve left ventricular function in patients with CHD.
To investigate the changes of plasma brain natriuretic peptide (BNP) concentrations in patients with chronic heart failure (CHF) before and after carvedilol treatment. Methods Plasma BNP concentrations of patients with CHF (n = 56) before and after carvedilol treatment and of normal controls (n = 60) were measured with specific radioimmunoassay. Left ventricular ejection fraction of patients with CHF before and after carvedilol was measured with 99mTc gated cardiac blood pool scintigraphy. Results The results showed that plasma BNP concentrations of patients with CHF were significantly higher than that of normal controls [(222.65 ± 78.52) ng · L -1 vs. (38.82 ± 15.31) ng · L -1, P <0.01]. Plasma BNP levels had a significant negative correlation with left ventricular ejection fractions (r = -0.68 , P <0.01). After three months treatment of carvedilol, plasma BNP concentrations fell to (79.65 ± 69.52) ng · L -1 (P <0.01), left ventricular ejection fractions increased from 34.41% ± 4.54% to 46.51% ± 5.38 % (P <0.01). Conclusions These results that that plasma BNP concentrations are increased in patients with CHF, and markedly increased according to the severity of heart failure classified by NYHA classification. Carvedilol can markedly decreased plasma BNP concentrations and improve left ventricular function in patients with CHD.